复方丹参注射液联合硝苯地平对妊娠期高血压疾病的疗效

doi:10.3969/j.issn.1006-5725.2026.15.003

摘要/Abstract

摘要：

目的探讨复方丹参注射液联合硝苯地平治疗妊娠期高血压疾病的临床疗效及其对氧化应激、血管内皮功能相关指标的影响。方法采用前瞻性随机对照试验，纳入2023年1月至2025年1月期间廊坊市妇幼保健院产科收治的90例妊娠期高血压疾病患者，将受试者随机分为对照组（n = 45）和观察组（n = 45）。对照组给予硝苯地平缓释片，观察组在此基础上联合复方丹参注射液治疗。比较两组患者治疗效果及治疗前后血清超氧化物歧化酶（superoxide dismutase，SOD）、内皮素-1（endothelin-1，ET-1）、24 h尿蛋白定量水平、血压［收缩压（systolic blood pressure，SBP）、舒张压（diastolic blood pressure，DBP）］及脐动脉血流动力学指标［收缩期峰值流速/舒张末期流速比值（systolic/diastolic ratio，S/D）、阻力指数（resistance index，RI）及搏动指数（pulsatility index，PI）］变化，记录两组患者不良妊娠结局发生情况。结果观察组总有效率显著高于对照组（95.56% vs. 80.00%，P < 0.05）。治疗后，两组血清SOD水平均较治疗前升高，ET-1水平均下降，但观察组改善更为显著（P < 0.05）；观察组SBP、DBP及24 h尿蛋白降低幅度均优于对照组（P < 0.05）；观察组PI、RI和S/D的降幅均优于对照组（P < 0.05）。观察组不良妊娠结局发生率显著低于对照组（P < 0.05）。两组均未出现严重药物相关不良反应。结论复方丹参注射液联合硝苯地平治疗妊娠期高血压疾病可协同提升血压控制效果，调节氧化应激和血管内皮功能，提示该中西医联合治疗方案具有较好的临床应用前景。

关键词: 妊娠期高血压疾病, 复方丹参注射液, 硝苯地平, 超氧化物歧化酶, 内皮素-1

Abstract:

Objective To evaluate the clinical efficacy of compound Danshen injection in combination with nifedipine for hypertensive disorders of pregnancy and to investigate its regulatory effects on oxidative stress and vascular endothelial function. Methods This prospective， controlled study recruited 90 consecutive patients with hypertensive disorders of pregnancy who were admitted to the Department of Obstetrics at Langfang Maternal and Child Health Hospital from January 2023 to January 2025. The participants were randomly allocated to either a control group （n = 45）， which received nifedipine monotherapy， or an observation group （n = 45）， which was administered nifedipine in combination with compound Danshen injection. The treatment efficacy， serum levels of superoxide dismutase （SOD） and endothelin-1 （ET-1）， 24-hour urinary protein quantification， blood pressure ［systolic blood pressure （SBP）， diastolic blood pressure （DBP）］， and umbilical artery hemodynamic parameters ［systolic/diastolic ratio （S/D）， resistance index （RI）， and pulsatility index （PI）］ were compared both before and after treatment. Adverse pregnancy outcomes were also documented. Results The overall response rate was significantly higher in the observation group than in the control group （95.56% vs. 80.00%， P < 0.05）. After treatment， both groups showed increased SOD levels and decreased ET-1 levels， and the degree of improvement was significantly greater in the observation group （P < 0.05）. The observation group had significantly greater reductions in SBP， DBP， and 24-hour urinary protein levels （P < 0.05）. Moreover， compared with the control group， the observation group had larger decreases in PI， RI， and S/D after treatment （P < 0.05）. The incidence of adverse pregnancy outcomes was significantly lower in the observation group （P < 0.05）. No serious drug-related adverse reactions were observed in either group during the treatment period. Conclusions Treatment with Compound Danshen injection in combination with nifedipine significantly facilitated blood pressure stabilization and enhanced oxidative stress and endothelial function indices in patients with hypertensive disorders of pregnancy. Therefore， this combination therapy may represent a more effective and clinically valuable intervention compared to conventional treatment alone.

Key words: hypertensive disorders of pregnancy, compound danshen injection, nifedipine, superoxide dismutase, endothelin-1

中图分类号:

R714.25

王娜,刘艳杰. 复方丹参注射液联合硝苯地平对妊娠期高血压疾病的疗效[J]. 实用医学杂志, 2026, 42(15): 2692-2697.

Na WANG,Yanjie LIU. Clinical efficacy of compound danshen injection combined with nifedipine in treating hypertensive disorders of pregnancy[J]. The Journal of Practical Medicine, 2026, 42(15): 2692-2697.

图/表 6

表1

表2

表3

表4

表5

表6

参考文献 23

[1]	US PREVENTIVE SERVICES TASK FORCE， BARRY MJ， NICHOLSON WK， et al. Screening for hypertensive disorders of pregnancy： US preventive services task force final recommendation statement［J］. JAMA， 2023， 330（11）： 1074-1082. DOI： 10.1001/jama.2023.16991 . doi: 10.1001/jama.2023.16991
	BARRY M J， NICHOLSON W K， SILVERSTEIN M， et al. Screening for hypertensive disorders of pregnancy： US preventive services task force final recommendation statement［J］. Jama， 2023， 330（11）： 1074. doi：10.1001/jama.2023.16991 . doi: 10.1001/jama.2023.16991
[2]	ZHAO X， KONG W. Global temporal trends in maternal hypertensive disorders incidence and mortality from 1990 to 2021 based on the global burden of disease study［J］. Sci Rep， 2025， 15： 9035. doi：10.1038/s41598-025-93673-3 . doi: 10.1038/s41598-025-93673-3
[3]	DONEL S， NOVRI D A， HAMIDY Y， et al. Effectiveness of nifedipine， labetalol， and hydralazine as emergency antihypertension in severe preeclampsia： A randomized control trial［J］. F1000Research， 2023， 11： 1287. doi：10.12688/f1000research.125944.2 . doi: 10.12688/f1000research.125944.2
[4]	ZHOU Y， WANG J， WANG L， et al. Effect of compound Danshen injection combined with magnesium sulfate on oxidative stress， TNF-α， NO， and therapeutic efficacy in severe preeclampsia［J］. Comput Intell Neurosci， 2022， 2022： 9789066. doi：10.1155/2022/9789066 . doi: 10.1155/2022/9789066
[5]	CHEN J， GU H， WU H， et al. Efficacy of Chinese patent medicines combined with conventional western medicine in treatment of preeclampsia： A systematic review and Bayesian network meta-analysis［J］. J Ethnopharmacol， 2025， 353： 120401. doi：10.1016/j.jep.2025.120401 . doi: 10.1016/j.jep.2025.120401
[6]	黄瑶，刘雅丽，王慧锦，等. 复方丹参注射液联合硫酸镁对子痫前期患者凝血指标及妊娠结局影响的Meta分析［J］. 中国中医急症， 2023， 32（3）： 387-392. doi：10.3969/j.issn.1004-745X. 2023.03.003 . doi: 10.3969/j.issn.1004-745X. 2023.03.003
[7]	樊阳阳，张京京，李秋敏. 丹参注射液联合小剂量阿司匹林治疗妊娠期高血压疾病的临床疗效及对患者血清相关指标的影响［J］. 药物评价研究， 2018， 41（12）： 2294-2298. doi： 10.7501/ j.issn.1674-6376.2018.12.032 . doi: 10.7501/ j.issn.1674-6376.2018.12.032
[8]	MAGEE L A， BROWN M A， HALL D R， et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification， diagnosis & management recommendations for international practice［J］. Pregnancy Hypertens， 2022， 27： 148-169. doi：10.1016/j.preghy.2021.09.008 . doi: 10.1016/j.preghy.2021.09.008
[9]	中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南（2020）［J］. 中华妇产科杂志， 2020， 55（4）： 227-238. doi：10.3760/cma.j.cn112141-20200114-00039 . doi: 10.3760/cma.j.cn112141-20200114-00039
[10]	刘俊，田福林，陈琳，等. 妊娠早期正常高值血压和1级高血压与孕产妇子痫前期及妊娠不良结局的关系［J］. 实用医学杂志， 2025， 41（10）： 1555-1562. doi：10.3969/j.issn.1006-5725. 2025.10.018 . doi: 10.3969/j.issn.1006-5725. 2025.10.018
[11]	PARAPOB N， LUEWAN S， KAMLUNGKUEA T， et al. Oxidative stress in pathogenesis of preeclampsia： Mechanistic and clinical insights［J］. Antioxidants， 2026， 15（3）： 387. doi：10.3390/antiox15030387 . doi: 10.3390/antiox15030387
[12]	AGARWAL G S， AGRAWAL A K， SINGHAL D， et al. Pregnancy-induced hypertension pathophysiology and contemporary management strategies： A narrative review［J］. Cureus， 2024， 16（7）： e63961. doi：10.7759/cureus.63961 . doi: 10.7759/cureus.63961
[13]	AWALUDIN A， RAHAYU C， DAUD N A A， et al. Antihypertensive medications for severe hypertension in pregnancy： A systematic review and meta-analysis［J］. Healthcare， 2022， 10（2）： 325. doi：10.3390/healthcare10020325 . doi: 10.3390/healthcare10020325
[14]	SONG Y， SONG N， JIA L， et al. Effectiveness and safety of Danshen injections in treatment of cardiac failure： A network meta-analysis［J］. Front Pharmacol， 2024， 15： 1319551. doi：10.3389/fphar.2024.1319551 . doi: 10.3389/fphar.2024.1319551
[15]	SHEN Q， WANG H， QUAN B， et al. Rapid quantification of bioactive compounds in Salvia miltiorrhiza Bunge derived decoction pieces， dripping pill， injection， and tablets by polarity-switching UPLC-MS/MS［J］. Front Chem， 2022， 10： 964744. doi：10.3389/fchem.2022.964744 . doi: 10.3389/fchem.2022.964744
[16]	WU Y T， ZHANG G Y， LI L， et al. Salvia miltiorrhiza suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling［J］. J Ethnopharmacol， 2024， 330： 118214. doi：10.1016/j.jep.2024.118214 . doi: 10.1016/j.jep.2024.118214
[17]	SU H， LI M， LI N， et al. Endothelin-1 potentiated constriction in preeclampsia placental veins： Role of ETAR/ETBR/CaV_1.2/CALD1［J］. Placenta， 2024， 158： 165-174. doi：10.1016/j.placenta.2024. 10.011 . doi: 10.1016/j.placenta.2024. 10.011
[18]	XU X J， LONG J B， JIN K Y， et al. Danshen-Chuanxiongqin Injection attenuates cerebral ischemic stroke by inhibiting neuroinflammation via the TLR2/TLR4-MyD88-NF-κB Pathway in tMCAO mice［J］. Chin J Nat Med， 2021， 19（10）： 772-783. doi：10.1016/S1875-5364（21）60083-3 . doi: 10.1016/S1875-5364（21）60083-3
[19]	ZHANG W， LI J， YANG P， et al. Efficacy and safety of Salvia miltiorrhiza for treating chronic kidney diseases： A systematic review and meta-analysis［J］. Evid Based Complementary Altern Med， 2022， 2022： 2117433. doi：10.1155/2022/2117433 . doi: 10.1155/2022/2117433
[20]	YU X， ZHOU Q. Effects of nifedipine tablets combined with magnesium sulfate on blood coagulation index， oxidative stress， NO and ET-1 levels in patients with pregnancy hypertension［J］. Front Surg， 2022， 9： 862676. doi：10.3389/fsurg.2022.862676 . doi: 10.3389/fsurg.2022.862676
[21]	刘永成，田颖，郭栋，等. 复方丹参滴丸治疗原发性高血压的系统评价和Meta分析［J］. 中草药， 2022， 53（10）： 3111-3124. doi：10.7501/j.issn.0253-2670.2022.10.022 . doi: 10.7501/j.issn.0253-2670.2022.10.022
[22]	周敏，张潇潇，吴钊. 阿司匹林对子宫内膜异位症合并薄型子宫内膜冻融胚胎移植的影响［J］. 实用医学杂志， 2025， 41（1）： 95-99. doi：10.3969/j.issn.1006-5725.2025.01.016 . doi: 10.3969/j.issn.1006-5725.2025.01.016
[23]	CHANG K J， SEOW K M， CHEN K H. Preeclampsia： Recent advances in predicting， preventing， and managing the maternal and fetal life-threatening condition［J］. Int J Environ Res Public Health， 2023， 20（4）： 2994. doi：10.3390/ijerph20042994 . doi: 10.3390/ijerph20042994

项目	观察组（n = 45）	对照组（n = 45）	t/χ²值	P值
年龄/岁	29.52 ± 3.16	29.93 ± 3.28	0.604	0.547
孕周/周	30.34 ± 2.57	30.62 ± 2.71	0.503	0.616
体质量指数/（kg/m²）	23.45 ± 2.63	23.96 ± 2.78	0.894	0.374
产妇类型/［例（%）］			0.741	0.389
初产妇	29（64.44）	25（55.56）
经产妇	16（35.56）	20（44.44）
妊娠期高血压疾病分类/［例（%）］			1.123	0.570
妊娠期高血压	23（51.11）	21（46.67）
轻度子痫前期	15（33.33）	13（28.89）
重度子痫前期	7（15.56）	11（24.44）

组别	显效	有效	无效	总有效
观察组（n = 45）	26（57.78）	17（37.78）	2（4.44）	43（95.56）
对照组（n = 45）	17（37.78）	19（42.22）	9（20.00）	36（80.00）
χ²值				5.075
P值				0.024

组别	SOD/（U/mL）		ET-1/（pg/mL）
组别	治疗前	治疗后	治疗前	治疗后
观察组（n = 45）	82.75 ± 10.49	108.65 ± 12.57^a	82.45 ± 9.32	64.19 ± 7.32^a
对照组（n = 45）	83.14 ± 10.83	95.76 ± 14.03^a	83.12 ± 9.78	71.26 ± 7.95^a
t值	0.174	4.590	0.333	4.389
P值	0.863	< 0.001	0.740	< 0.001

组别	SBP/mmHg		DBP/mmHg		24 h尿蛋白/g
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组（n = 45）	153.72 ± 8.03	132.58 ± 6.39^a	98.45 ± 5.63	87.14 ± 5.42^a	2.38 ± 0.87	1.35 ± 0.51^a
对照组（n = 45）	154.10 ± 8.21	141.05 ± 6.74^a	98.96 ± 5.78	93.60 ± 6.23^a	2.42 ± 0.92	1.80 ± 0.68^a
t值	0.222	6.118	0.424	5.248	0.212	3.551
P值	0.825	< 0.001	0.673	< 0.001	0.833	0.001

组别	PI		RI		S/D
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组（n = 45）	1.09 ± 0.17	0.64 ± 0.08^a	0.84 ± 0.15	0.46 ± 0.06^a	3.49 ± 0.48	2.36 ± 0.25^a
对照组（n = 45）	1.12 ± 0.21	0.79 ± 0.12^a	0.88 ± 0.16	0.67 ± 0.09^a	3.41 ± 0.42	2.59 ± 0.30^a
t值	0.745	6.977	1.223	13.024	0.841	3.951
P值	0.458	< 0.001	0.224	< 0.001	0.402	< 0.001